1.Advances in the treatment of age-related macular degeneration: A review
Uy Harvey Siy ; Chan Pik Sha T ; Veloso Amado
Philippine Journal of Ophthalmology 2003;28(2):111-119
Objective: To review the latest developments in the treatment of age-related macular degeneration (AMD). Method: Literature review Results: The treatment of AMD is rapidly evolving. New developments in the biophysical, biochemical and clinical sciences and greater understanding of the pathophysiology of AMD are being used to produce new treatment strategies Conclusion: While several promising novel treatment approaches are being developed for the treatment of AMD, treatment recommendations should be based on results of well-designed randomized clinical trials.
Human
;
Aged
;
Middle Aged
;
LITERATURE REVIEW
;
RADIOTHERAPY
;
LASER SURGERY
2.Pegaptanib sodium for macular edema due to retinal-vein occlusion among patients intolerant to intravitreal triamcinolone acetonide
Ellen N. Yu ; Pik Sha Chan ; Amadeo A.S. Veloso ; Harvey S Uy
Philippine Journal of Ophthalmology 2010;35(2):79-81
Objective:
To report the efficacy and safety of intravitreal pegaptanib sodium (IVP)
on macular edema (ME) due to branch retinal-vein occlusion (BRVO) among
patients intolerant to intravitreal triamcinolone acetonide (IVTA).
Methods:
Four eyes with ME due to BRVO were included in this interventional case
series. The main outcome measures were best-corrected visual acuity (BCVA),
central macular thickness (CMT), intraocular pressure (IOP), and adverse
effects.
Results:
There was a significant decrease in mean CMT from 524.50 ± 141.12 to
293.75 ± 130.75 microns (p = 0.009) after IVP injection. BCVA improved in all
4 eyes after IVP. Mean IOP after IVP was 13.60 ± 3.21. No ocular or systemic
complications were observed.
Conclusion
IVP appears to be safe and effective in decreasing retinal thickness and
improving VA in eyes with ME due to BRVO. IVP is a potential treatment for
eyes that are intolerant to IVTA.
Macular Edema
3.Angle-supported intraocular-lens implantation for the correction of moderate to high myopia
Kevin Matthew Serafin B. Panggat ; Jesus Francisco, III ; Pik Sha Chan ; Harvey Siy Uy
Philippine Journal of Ophthalmology 2011;36(1):33-37
Objectives:
This study evaluated the efficacy and safety of an angle-supported phakic intraocular lens (PIOL) for the treatment of moderate to high myopia.
Methods :
This is a case series of 13 eyes of 8 patients with moderate to high myopia that underwent implantation of an acrylic, angle-supported PIOL. The main outcome measures were manifest refraction, uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), endothelial-cell count (ECC), intraocular pressure (IOP), and adverse events.
Results:
The mean spherical equivalent (SE) improved from –11.79 ± 4.12 diopters (D) preoperatively to –0.08 ± 0.58 D postoperatively (p = 0.000), UCVA from 0.016 ± 0.015 to 0.79 ± 0.29 postoperatively (p = 0.000), and BCVA from 0.76 ± 0.33 to 0.86 ± 0.27 (p = 0.017). The ECC slightly decreased from 3033.57 ± 367.71 cells/mm2 preoperatively to 2947 ± 279.86 cells/mm2 (2.8% loss) postoperatively (p = 0.400). The mean preoperative IOP was 16.36 ± 3.53 mm Hg while the mean three-month postoperative IOP was 15.72 ± 4.15 mm Hg (p = 0.659). Two (15%) eyes experienced transient postoperative IOP rise on the day of the surgery, which resolved by postoperative day 1 using topical timolol maleate. The mean follow-up was 2.54 ± 1.39 months (range, 1 to 5 months).
Conclusion
Acrylic angle-supported phakic intraocular lens (PIOL) implantation is an effective and safe method of correcting moderate to high myopia.
Refractive Surgical Procedures
4.Postoperative safety outcomes in patients undergoing routine Phacoemulsification Cataract Surgery with Intraoperative Intracameral Injection of Preservative-Free Moxifloxacin versus Levofloxacin
Franz Marie Cruz ; Harvey S. Uy ; Carlo Josemaria Rubio ; Pik Sha Chan
Philippine Journal of Ophthalmology 2022;47(1):15-22
Purpose:
This study compared the safety outcomes of two intracameral fluoroquinolone antibiotics,
moxifloxacin and levofloxacin, as prophylaxis treatment in eyes that underwent uncomplicated cataract surgery.
Methods:
This is a prospective, double-masked, randomized, interventional, single-center clinical trial. Eyes
with visually-significant cataracts underwent phacoemulsification and received preservative-free intracameral
0.5% moxifloxacin [58 eyes (M group)] or 0.5% levofloxacin [56 eyes (L group)] at the end of the surgery as
antibiotic prophylaxis. The following safety parameters were evaluated postoperatively at Day 1, Week 1 and
Month 1: central retinal thickness (CRT), macular volume (MV), central corneal thickness (CCT), and
endothelial cell density (ECD). In-between group comparison was made at each of the 4 study visits using
Student’s t-test.
Results:
Both M and L groups had similar baseline characteristics. There were no significant differences in
CRT, MV, CCT and ECD between the 2 groups at each time point in the study. There were no significant
differences in the mean changes in CRT, MV, CCT and ECD from baseline to final visit between the 2 groups.
No study-related adverse events were observed during the study period.
Conclusion
Intracameral application of preservative-free 0.5% moxifloxacin and 0.5% levofloxacin appear to
have similar safety outcomes when used as antibacterial prophylaxis among eyes undergoing cataract surgery.
Based on the results, both fluoroquinolone agents are potentially suitable options for endophthalmitis
chemoprophylaxis.
Levofloxacin
;
Moxifloxacin
;
Fluoroquinolones